

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

1316456

OMB APPROVAL

OMB NUMBER: 3235-0076

Expires: April 30, 2008 Estimated average burden hours per

response 16.00



Name of Offering (check if this i	of Offering (check if this is an amendment and name has changed, and indicate change.)							
Series B Convertible Preferred Stock					069438			
Filing Under (Check box(es) that apply): Type of Filing: ■ New Filing □ Ame	☐ Rule 504 endment	□ Rule 505	■ Rule 506	☐ Section 4(6)	ULOE			
A. BASIC IDENTIFICATION DATA								
 Enter the information requested a 	about the issuer							
Name of Issuer (check if this is	an amendment and nar	ne has changed, and indi	cate change.)					
Abeille Pharmaceuticals, Inc.								
Address of Executive Officers	(Number and Street	, City, State, Zip Code)	Telephone Nu	ımber (Including Area Co	de)			
Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 609.951.2204								
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street	, City, State, Zip Code)	Telephone Nu	imber (Including Area Co	de)			
Brief Description of Business	• • • • • • • • • • • • • • • • • • • •	- College - Coll						
Development of pharmaceutical product	s.				DDOOF			
Type of Business Organization					THUUESSEN			
	☐ limited partr	ership, already formed	□ other (please specify):				
☐ business trust	☐ limited partr	ership, to be formed			OCT 2 4 2005			
Actual or Estimated Date of Incorporation of Jurisdiction of Incorporation or Organization	or Organization: on: (Enter two-letter U	onth Year 11 03 J.S. Postal Service abbre FN for other foreign juris		imated	THOMSON FINANCIAL			

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issues making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to the address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 OF 10



A. BASIC IDENTIFICATION DATA 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: Beneficial Owner ☐ Promoter Executive Officer ☑ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Borsadia, Suresh Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 Check Box(es) that Apply: ☐ Promoter Beneficial Owner □ Executive Officer ☑ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Patel, Kalpana Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 Check Box(es) that Apply: ☐ Promoter Beneficial Owner ☐ Executive Officer ☐ General and/or Director Managing Partner Full Name (Last name first, if individual) Bhalani, Vinayak Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 Check Box(es) that Apply: ☐ Executive Officer ☐ Promoter ■ Beneficial Owner ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Patel, Dinesh Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 ☐ Executive Officer Check Box(es) that Apply: ☐ Promoter Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Patel, Pradip · Business or Residence Address (Number and Street, City, State, Zip Code) 106 South Hoover Blvd., Tampa, Florida 33609 ☐ Director ☐ General and/or ☐ Executive Officer Check Box(es) that Apply: ☐ Promoter ■ Beneficial Owner Managing Partner Full Name (Last name first, if individual) Innovative Medical Technology Foundation Business or Residence Address (Number and Street, City, State, Zip Code) 119-123 Sandycombe Road, Richmond, Surrey TW92EP, United Kingdom Check Box(es) that Apply: ☐ Promoter ■ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Patel, Rajendra Business or Residence Address (Number and Street, City, State, Zip Code) 16 Nolan Circle, Voorhees, NJ 08043 Check Box(es) that Apply: ☐ Promoter □ Beneficial Owner ☐ Executive Officer ☑ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Lavotha, Zsolt Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

A. BASIC IDENTIFICATION DATA (CONTINUED) 2. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer: Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: □ Promoter ☐ Beneficial Owner ☐ Executive Officer ☑ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Warren, Jr., James Business or Residence Address (Number and Street, City, State, Zip Code) c/o Abeille Pharmaceuticals, Inc., Princeton Forrestal Village, 116 Village Boulevard, Suite 200, Princeton, NJ 08540-5799 Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director Check Box(es) that Apply: ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) ☐ Executive Officer Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: □ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual)

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

Business or Residence Address (Number and Street, City, State, Zip Code)

B. INFORMATION ABOUT OFFERING													
.1	Has the is	suer sold, or	does the iss	suer intend t	o sell, to no	n-accredited	investors in	this offering	g?			Yes	No 🗷
	Answer also in Appendix, Column 2, if filing under ULOE.								_				
2.	What is th	e minimum	investment	that will be	accepted fro	om any indiv	idual?					\$N/A	
3.	Does the o	offering perr	mit joint own	nership of a	single unit?					•••••••••		Yes ∑	No
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar renumeration for solication of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.													
Full Na	me (Last nan	ne first, if in	dividual)										
Busines	s or Residen	ce Address (Number and	Street, City	y, State, Zip	Code)				timt.			
Name o	f Associated	Broker or D	ealer				.,						
Carani	Which Pers	1 4 11	C-11-14-1	T J	. C. 1'-i- D		***						
States if												□ All S	tates
	AL IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	ID MO PA PR
Full Na	me (Last nan	ne first, if in	dividual)									_	
								_					
Busines	s or Residen	ce Address (Number and	d Street, City	y, State, Zip	Code)							
Name o	f Associated	Broker or D	Dealer										
States in	Which Pers												
	· —			_			,				_	☐ All S	
	AL	AK IN	AZ	AR	CA	co	CT	DE MD	DC MA	FL MI	GA	HI MS	MO
	IL MT	NE	NV NV	KS NH	KY NJ	LA NM	ME NY	NC	ND	ОН	MN OK	OR	PA
	RI	SC	SD	TN	TX	UT	VT	VA	WA]	[WV]	WI	WY	PR
Full Name (Last name first, if individual)									لنيتا				
Business or Residence Address (Number and Street, City, State, Zip Code)													
Name o	f Associated	Broker or D	Dealer										
States in Which Person Listed Has Solicited or Intends to Solicit Purchasers													
	(Check "All States" or check individual States)								☐ All S	States			
	AL	AK	AZ	AR	CA	co	[CT]	DE	DC	FL	GA	НІ	ID
					1 1	LA	ME	MD	MA	MI	MN	INACL	
	IL MT	IN NE	IA NV	KS NH	KY NJ	NM	NY	NC	ND	ОН	ОК	MS OR	MO

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if the answer is "none" or "zero." If the transaction is an exchange offering, check this box
and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Amount Aggregate Types of Security Offering Price Already Sold Debt \$ 5,000,000* \$ 600,000* Equity □ Common

Preferred Convertible Securities (including warrants)..... Partnership Interests Other (Specify ______) Total \$ 5,000,000 \$ 600,000 Answer also in Appendix, Column 3, if filing under ULOE. *Represents the value of the Common Stock into which the Series B Convertible Preferred Stock is convertible 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Aggregate Dollar Number Investors Amount of Purchases Accredited Investors \$ 600,000 Non-accredited Investors Total (for filings under Rule 504 only) Answer also in Appendix, Column 4, if filing under ULOE. 3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of Dollar Type of Offering NOT APPLICABLE Security Amount Sold Rule 505 Regulation A Rule 504 Total a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees Printing and Engraving Costs \$_8,500 Legal Fees Accounting Fees Engineering Fees Sales Commissions (specify finders' fees separately) Other Expenses (identify)

Total

\$<u>8,500</u>

	C. OFFERING PRICE, NU	MBER OF INVESTORS, EXPENSES AND USE	OF PROCEEDS	}	
-	- Question 1 and total expenses furnish	gregate offering price given in response to Part C hed in response to Part C – Question 4.a. This eds to the issuer."			
l 1	Indicate below the amount of the adjusted used for each of the purposes show furnish an estimate and check the box payments listed must equal the adjusted to Part C – Question 4.b above.		\$ <u>4,991,500</u>		
			Payments to Officers, Directors, & Affiliates	Payments to Others	
9	Salaries and fees		□ \$	\$	
J	Purchase of real estate		□ \$	□ \$	
	Purchase, rental or leasing and installa and equipment	□ \$	□ \$		
(Construction or leasing of plant buildi	□ \$	□ \$		
(offering that may be used in exchange	ling the value of securities involved in this for the assets or securities of another	□\$		
	Repayment of indebtedness		□ \$		
	Working capital		≥ \$ 4,991,500		
	Other (specify): Research programs, ir		□ \$		
(Column Totals	□ \$	≥ \$ <u>4,991,500</u>		
-	Total Payments Listed (column totals a	■ \$ <u>4,991,500</u>			
· · · · · · · · · · · · · · · · · · ·		D. FEDERAL SIGNATURE		_	
the follow	ving signature constitutes an undertaki	ned by the undersigned duly authorized person. If the ing by the issuer to furnish to the U.S. Securities and ished by the issuer to any non-accredited investor pure	Exchange Commi	ssion, upon	
	rint or Type) E PHARMACEUTICALS, INC.	Signature & Mesh B	Date 10/19/0	5	
	Signer (Print or Type)	Title of Signer (Print or Type)	1 1	-	
Suresh B	Borsadia	President			

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)